# DESCRIPTION

## FIELD OF THE INVENTION

- relate to glycoconjugate vaccine

## BACKGROUND TO THE INVENTION

- introduce vaccines
- limitations of subunit vaccines
- application of glycoconjugates
- motivate novel glycoconjugate production

## STATEMENT OF INVENTION

- define vaccine composition
- describe carrier polypeptide
- detail antigenic polysaccharide
- specify O-antigen structure
- describe preferred embodiments of O-antigen
- detail protein carrier sequences
- describe adjuvant options
- specify cytokine adjuvants
- describe TLR agonist adjuvants
- detail bacterial cell wall derivative adjuvants
- define adjuvant function
- describe carrier function
- detail multivalent antigenic composition
- describe additional anti-bacterial agents
- specify antibiotic anti-bacterial agents
- describe vaccine composition for Francisella infection
- describe method to treat Francisella infection
- define antigenic polypeptide
- describe modified bacterial cell
- detail hybridization conditions

## Materials and Methods

### Bacterial Strains and Plasmids

- describe bacterial strains and plasmids

### Cloning, Sequencing and Expression of the F. Tularensis O Antigen Coding Region

- clone and sequence F. tularensis O antigen coding region

### Production and Purification of Glycoconjugate Vaccine

- produce glycoconjugate vaccine
- purify glycoconjugate vaccine using Ni-NTA agarose
- further purify glycoconjugate vaccine using resource Q anionic exchange column
- estimate protein yields using bicinchonic acid assay kit

### Immunoblot Analysis

- analyze samples by western blotting

### Cytokine Response Analysis

- assess cytokine response using mouse inflammatory cytometric bead array kit

### BALB/c Mouse Challenge Studies

- conduct mouse challenge studies to evaluate vaccine efficacy

### Statistical Analysis

- perform statistical analysis using PASW program

## Production and Purification of Glycoconjugate Vaccine

- produce glycoconjugate vaccine
- purify glycoconjugate vaccine using Ni-NTA agarose and resource Q anionic exchange column

### Protein Expression

- express and purify His-tagged ExoA

## EXAMPLE 1

### Expression of the F. tularensis SchuS4 O-Antigen in E. coli DH5α Cells

- express F. tularensis O antigen in E. coli DH5α cells

## EXAMPLE 2

### CjPgIB can Transfer F. tularensis O-Antigen to the Acceptor Protein Exotoxin A

- demonstrate transfer of F. tularensis O antigen to ExoA

## EXAMPLE 3

### Vaccination with the Glycoconjugate Provides Significant Protection Against F. tularensis Subsp. Holarctica Infection in Mice

- evaluate vaccine efficacy in mouse challenge studies

## EXAMPLE 4

### Mice Vaccinated with Test Glycoconjugate and Challenged with F. tularensis Subsp. Holarctica have Lower Bacterial Loads and Pro-Inflammatory Cytokines 3 Days Post Challenge

- evaluate bacterial loads and inflammatory responses

### EXAMPLE 5

- assess IgG immune response

